Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.36 |
| ▸ | CTRC | Q99895 | 1/20 | 0.35 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.35 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.35 |
| ▸ | CETP | P11597 | 3/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | TLR2 | O60603 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | AR | P10275 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9863407 | 0.88 | PLA2G2C (0.44) | CNR2PLA2G2CCTRCPLA2G10PLA2G2A | |
| SCHEMBL25967516 | 0.88 | PLA2G2C (0.44) | CNR2PLA2G2CCTRCPLA2G10PLA2G2A | |
| SCHEMBL9723718 | 0.81 | PLA2G2C (0.44) | PLA2G2CALDH1A1SMN1; SMN2CA1CA2 | |
| SCHEMBL9512608 | 0.81 | PLA2G2C (0.44) | PLA2G2CALDH1A1SMN1; SMN2CA1CA2 | |
| SCHEMBL9488453 | 0.81 | PLA2G2C (0.44) | PLA2G2CALDH1A1SMN1; SMN2CA1CA2 | |
| SCHEMBL1396102 | 0.81 | LMNA (0.45) | CNR2MAPTALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL9723827 | 0.80 | PLA2G2C (0.42) | PLA2G2CALDH1A1SMN1; SMN2LMNACA1 | |
| SCHEMBL25909329 | 0.80 | PLA2G2C (0.42) | CNR2PLA2G2CMAPTALDH1A1LMNA | |
| SCHEMBL19067483 | 0.79 | LMNA (0.39) | CNR2MAPTALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL11513138 | 0.78 | CNR2 (0.38) | CNR2PLA2G2CCTRCMAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230233593-A1 | ORALLY-BIOAVAILABLE NUCLEOSIDE ANALOGS | VenatoRx Pharmaceuticals, Inc. | 2023-07-27 | — | — | US | disclosed |
| US-11638715-B2 | Orally-bioavailable nucleoside analogs | VenatoRx Pharmaceuticals, Inc. (US) | 2023-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11638715-B2 | Orally-bioavailable nucleoside analogs | SLC29A2, SLC29A1, PNP | CNR2 3534/4885PLA2G2C 3210/4885CTRC 3479/4885 |
| US-20230233593-A1 | ORALLY-BIOAVAILABLE NUCLEOSIDE ANALOGS | SLC29A2, SLC29A1, PNP | CNR2 3534/4885PLA2G2C 3210/4885CTRC 3479/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.